Amphastar P
$ 21.38
0.09%
14 Apr - close price
- Market Cap 981,538,000 USD
- Current Price $ 21.38
- High / Low $ 21.70 / 21.11
- Stock P/E 10.03
- Book Value 17.28
- EPS 2.13
- Next Earning Report 2026-05-06
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.06 %
- ROE 0.13 %
- 52 Week High 31.26
- 52 Week Low 17.03
About
Amphastar Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company is headquartered in Rancho Cucamonga, California.
Analyst Target Price
$28.00
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-04 | 2025-11-06 | 2025-08-07 | 2025-05-06 | 2025-02-26 | 2024-11-06 | 2024-08-07 | 2024-05-10 | 2024-02-29 | 2023-11-08 | 2023-08-08 | 2023-05-09 |
| Reported EPS | 0.73 | 0.93 | 0.85 | 0.74 | 0.92 | 0.96 | 0.94 | 1.04 | 0.88 | 1.15 | 0.65 | 0.62 |
| Estimated EPS | 0.9251 | 0.8277 | 0.74 | 0.6877 | 0.9383 | 1 | 0.77 | 0.96 | 0.93 | 0.69 | 0.56 | 0.48 |
| Surprise | -0.1951 | 0.1023 | 0.11 | 0.0523 | -0.0183 | -0.04 | 0.17 | 0.08 | -0.05 | 0.46 | 0.09 | 0.14 |
| Surprise Percentage | -21.0896% | 12.3596% | 14.8649% | 7.6051% | -1.9503% | -4% | 22.0779% | 8.3333% | -5.3763% | 66.6667% | 16.0714% | 29.1667% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-06 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | 0.6 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: AMPH
2026-04-12 00:39:12
The article title, "Do options traders know something about Amphastar Pharmaceuticals stock we don't?", suggests a market analysis focusing on Amphastar Pharmaceuticals (AMPH) and the implications of options trading activity. It hints at exploring whether unusual options market behavior might signal future stock movements or insider knowledge that the general public and other investors are not yet privy to. Without the full article, specific details about the nature of the options activity or the conclusions drawn are not available.
2026-04-08 22:09:06
This article provides a financial overview of Amphastar Pharmaceuticals, Inc (AMPH), detailing its revenue breakdown, profitability margins, and a comparison with competitors. The company's largest revenue contributor is "Other finished pharmaceutical products," and its gross margin stands at 46.79%. A competitive analysis against AKTS and PCRX is also presented.
2026-04-08 15:10:19
Barclays has lowered its price target for Amphastar Pharmaceuticals (NASDAQ:AMPH) to $23.00 from $30.00, maintaining an "equal weight" rating. This adjustment comes after the company recently missed quarterly earnings and revenue estimates. The new target implies a potential upside of approximately 12% from its previous close, with the stock currently holding an average "Hold" rating from analysts.
2026-04-08 10:28:00
This article analyzes potential momentum shifts for Amphastar Pharmaceuticals Inc. (AMPH) using AI models. It highlights strong near and mid-term sentiment, a tested support level, and an exceptional risk-reward setup targeting a 20.1% gain. The piece also outlines three distinct trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—tailored for different risk profiles and holding periods, along with multi-timeframe signal analysis.
2026-04-08 10:09:45
Amphastar Pharmaceuticals (NASDAQ:AMPH) has received an average "Hold" rating from eight brokerages, with a consensus 1-year target price of $29.50. The company recently missed Q4 earnings estimates, reporting $0.73 EPS against an expected $0.97 and revenue of $183.11 million compared to $190.48 million. Despite institutional investors increasing their holdings, the stock trades with a P/E of 10.14 and has seen several analyst target price reductions.
2026-04-06 10:11:07
Amphastar Pharmaceuticals, Inc. announced that its CFO, EVP of Regulatory Affairs and Clinical Operations, and SVP of Corporate Communication will be presenting at the 25th Annual Needham Healthcare Conference on April 14, 2026. A webcast of the presentation will be available on the company's investor relations website for 30 days following the event. Amphastar Pharmaceuticals focuses on developing, manufacturing, and commercializing technically challenging generic and proprietary injectable, inhalation, and intranasal products.
